About US
Contact us
-
Sackler family, Purdue Pharma boost multistate opioid settlement to $7.4B in new agreementIn the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the now-bankrupt Purdue Pharma, the Sacklers, has come back from last year’s Supre2025/1/26
-
Fierce Pharma Asia—Takeda R&D chief's new strategy; AZ, Daiichi's ADC nod; Fosun's failed Henlius buyTakeda's R&D chief explained the company's new investment priorities. AstraZeneca and Daiichi Sankyo's second antibody-drug conjugate has won its initial FDA approval in breast cancer. Fosun Phar2025/1/23
-
Preeclampsia nonprofit puts new spin on old drug to close maternal health equity gapThe Preeclampsia Foundation hasfounda formula for closing the maternal health equity gap: Mix one part equity-forward preeclampsia education with one part low-dose aspirin prophylaxis and voilà, you2025/1/23
-
Teva's multiple sclerosis stalwart Copaxone gets FDA boxed warning for anaphylaxis riskAfter years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update, which also a2025/1/21
-
Fosun's proposed Henlius Biotech buyout fails to pass shareholder voteFosun International’s proposed buyout of its partially owned subsidiary, Shanghai Henlius Biotech, has been quashed, with the necessary threshold of Henlius’ shareholders not voting in favor of the d2025/1/21
-
Samsung Biologics sidesteps CDMO industry trend with 23% growth in 2024After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, including Lonza,Thermo FisherandCatalent. But Korean powerhouse Samsung Biolo2025/1/16
-
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take holdAs Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the s2025/1/16
-
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapyAlready on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA hasblessedthe nasal spray to be used as a monotherapy for major dep2025/1/14
-
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubsDespite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme. T2025/1/14
-
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer'sAs evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepatide2025/1/9